M. Laura Martin, PhD

Assistant Professor of Research in Systems and Computational Biomedicine (Courtesy)

Contact & profiles

Appointments

Assistant Professor of Research in Systems and Computational Biomedicine (Courtesy)Primary
Systems and Computational Biomedicine · 2025–

Past Appointments

Assistant Professor of Research in Physiology and Biophysics (Courtesy)
Systems and Computational Biomedicine · 2022–2025
Assistant Professor of Research in Physiology and Biophysics
Systems and Computational Biomedicine · 2022–2022
Research Associate in Physiology and Biophysics
Systems and Computational Biomedicine · 2019–2022

Show all 4

Centers

Education

Ph.D., Biotechnology, Genetic and Cell Biology
University of the Balearic Islands (Spain), 2011
M.S., Biotechnology, Genetic and Cell Biology
University of the Balearic Islands (Spain), 2009
B.S., Biology
National University of Mar del Plata (Argentina), 2006

Publications

2 grants

Co-I
Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory
U.S. Department of Defense · 2021–2026
W81XWH-21-2-0034
Co-I
Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity.
U.S. Department of Defense · 2021–2026
W81XWH-21-1-0762

Completed grants (4)

KP
Research collaboration agreement w/ Eli Lilly and Company
Eli Lilly and Company · 2019–2025BioPharma Alliance
ELC 202676-03
Co-I
Unraveling the landscape of homologous recombination deficiency in patients with breast and prostate cancer across the African diaspora in NYC
New York Genome Center Inc. · 2020–2024
NYG 204878-01
Co-I
The DARC side of Breast Cancer Disparities - African Ancestry and Cancer- Related Immune Response
National Cancer Institute · 2021–2023
R01CA259396-01
Co-I
Clinical and Translational Science Center - UL1
National Center for Advancing Translational Sciences · 2017–2022
UL1TR002384-01

Tumor Organoid Tech Advances Toward a Sci-Fi Future
July 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.